(September 17, 2012) -- Speaking to an audience of health care providers in early August, FTC Commissioner Julie Brill focused her comments on initiatives that sustain health care competition. She noted recent progress including a landmark appellate court decision that affirms FTC objections to pay-for-delay. These sweetheart deals between brand name drug companies and generic rivals end patent litigation in exchange for delaying the arrival of generic drugs. Competing rulings in different circuits mean that pay-for-delay may head for the Supreme Court, where Brill is confident that the FTC’s position can prevail....